A 5,116-participant study found that patients who are at risk of thromboembolism are more likely to suffer thromboembolic events if they are not treated with anticoagulants following cardioversion of acute atrial fibrillation. The results affirm the European Society of Cardiology's 2010 recommendation that acute AF patients receive anticoagulants, specifically heparin peri-cardioversion followed by long-term use of a vitamin K antagonist during and after restoration of normal heart rhythm.
Thromboembolic risk rises without anticoagulants after cardioversion
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan